- Home
- BLUE vs BIVI Comparison
BLUE vs BIVI Comparison
Compare BLUE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- BIVI
- Stock Information
- Founded
- BLUE 1992
- BIVI 2013
- Country
- BLUE United States
- BIVI United States
- Employees
- BLUE N/A
- BIVI N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- BLUE Health Care
- BIVI Health Care
- Exchange
- BLUE Nasdaq
- BIVI Nasdaq
- Market Cap
- BLUE 62.1M
- BIVI 49.8M
- IPO Year
- BLUE 2013
- BIVI N/A
- Fundamental
- Price
- BLUE $4.08
- BIVI $1.48
- Analyst Decision
- BLUE Hold
- BIVI Strong Buy
- Analyst Count
- BLUE 9
- BIVI 1
- Target Price
- BLUE $49.14
- BIVI $30.00
- AVG Volume (30 Days)
- BLUE 458.1K
- BIVI 596.3K
- Earning Date
- BLUE 03-25-2025
- BIVI 02-11-2025
- Dividend Yield
- BLUE N/A
- BIVI N/A
- EPS Growth
- BLUE N/A
- BIVI N/A
- EPS
- BLUE N/A
- BIVI N/A
- Revenue
- BLUE $53,120,000.00
- BIVI N/A
- Revenue This Year
- BLUE $145.30
- BIVI N/A
- Revenue Next Year
- BLUE $240.19
- BIVI N/A
- P/E Ratio
- BLUE N/A
- BIVI N/A
- Revenue Growth
- BLUE 144.50
- BIVI N/A
- 52 Week Low
- BLUE $4.00
- BIVI $1.04
- 52 Week High
- BLUE $38.40
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- BLUE 26.22
- BIVI 32.72
- Support Level
- BLUE $6.61
- BIVI $1.45
- Resistance Level
- BLUE $7.55
- BIVI $1.88
- Average True Range (ATR)
- BLUE 0.64
- BIVI 0.16
- MACD
- BLUE -0.11
- BIVI -0.01
- Stochastic Oscillator
- BLUE 2.24
- BIVI 5.08
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.